<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Autoimmune pancreatitis: Clinical manifestations and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Autoimmune pancreatitis: Clinical manifestations and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Autoimmune pancreatitis: Clinical manifestations and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas G Adler, MD, FACG, AGAF, FASGE</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence S Friedman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 04, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Autoimmune pancreatitis (AIP) is an uncommon but well-established form of pancreatic inflammation. Unlike other pancreatic diseases, it typically has a dramatic response to glucocorticoid therapy. AIP can appear radiographically as a focal mass that is indistinguishable from pancreatic cancer or as a diffuse pancreatic process that can be pathognomonic for AIP. If untreated, AIP can lead to pancreatic insufficiency, fibrosis, and other complications. The discovery of elevated immunoglobulin G4 (IgG4) as a biomarker of AIP helped establish the disorder as distinct from other forms of chronic pancreatitis; although, later studies demonstrated that IgG4 levels are often normal in AIP and that other diseases such as pancreatic cancer may be associated with moderately elevated IgG4 levels.</p><p class="headingAnchor" id="H1387998172"><span class="h1">EPIDEMIOLOGY AND CLASSIFICATION</span></p><p class="headingAnchor" id="H726187325"><span class="h2">Prevalence</span><span class="headingEndMark"> — </span>Autoimmune pancreatitis (AIP) has been reported worldwide, but the overall prevalence is higher in Asia than in the Americas, Europe, or Africa. Type 1 AIP is the more common form and represents the vast majority of cases in Asia. Type 2 AIP is more common in Europe and the United States than in Asia but remains a minor subtype.</p><p class="headingAnchor" id="H3571293826"><span class="h2">Subtypes</span><span class="headingEndMark"> — </span>AIP is a syndrome defined by clinical, laboratory, and pathologic criteria [<a href="#rid1">1</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type 1 AIP</strong> – Type 1 AIP is defined histologically as lymphoplasmacytic sclerosing pancreatitis (LPSP). The International Consensus Diagnostic Criteria (ICDC) defined type 1 AIP as: dense infiltration of plasma cells and lymphocytes, particularly periductal; storiform (a swirling, "cartwheel" pattern) fibrosis; venulitis with lymphocytes and plasma cells, often leading to obliteration of the affected veins; and abundant (&gt;10 cells per high-power field [HPF]) immunoglobulin G4 (IgG4)-positive plasma cells [<a href="#rid1">1</a>]. Type 1 AIP may present as an isolated disorder or as part of an IgG4-related disease (IgG4-RD) syndrome with other organ involvement (OOI). (See <a class="local">'Clinical manifestations'</a> below and <a class="local">'Histology'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type 2 AIP </strong>– Type 2 AIP is defined histologically as idiopathic duct-centric pancreatitis (IDCP) or AIP with granulocyte epithelial lesions (GELs). The GEL lesions are intraluminal and intraepithelial neutrophils in medium-sized and small ducts as well as in acini, often leading to the destruction and obliteration of the duct lumen [<a href="#rid1">1</a>]. IDCP usually has very few IgG4-positive plasma cells (&lt;10 cells/HPF). Type 2 AIP appears to be limited to the pancreas and often co-occurs in patients with inflammatory bowel disease (IBD). (See <a class="local">'Clinical manifestations'</a> below and <a class="local">'Histology'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>AIP NOS</strong> – AIP NOS<strong> </strong>is a term to classify patients who do not meet criteria for type 1 or type 2 AIP. Tissue may not be available for histology, and they do not have markedly elevated serum IgG4 levels, OOI (as in type 1 AIP), or IBD (as in type 2 AIP) [<a href="#rid1">1,2</a>].  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IgG4-RD</strong> – IgG4-RD is an immune-mediated fibroinflammatory condition that is capable of affecting multiple organs. It is characterized by multi-organ involvement, serum IgG4 elevation, and infiltration of the affected organs with IgG4-positive plasma cells [<a href="#rid3">3-5</a>]. Type 1 AIP is one of the most common features of this systemic syndrome. IgG4-related sclerosing cholangitis (IgG4-SC) is cholangitis associated with elevated serum IgG4 levels, dense infiltration of IgG4-positive plasma cells with storiform fibrosis, and/or obliterative phlebitis in the bile duct wall and good response to glucocorticoids [<a href="#rid6">6,7</a>]. IgG4-SC and type 1 AIP often overlap as a pancreatobiliary syndrome within the IgG4-RD spectrum.</p><p></p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H1416354517"><span class="h2">Clinical features</span></p><p class="headingAnchor" id="H3367539244"><span class="h3">Type 1 AIP</span><span class="headingEndMark"> — </span>Patients with autoimmune pancreatitis (AIP) most commonly present with painless obstructive jaundice. More than one-third of cases are discovered in asymptomatic patients undergoing evaluation for a pancreatic mass, pancreatic enlargement, or pancreatic duct strictures on abdominal imaging; a cholestatic pattern of liver test elevation; or diabetes mellitus [<a href="#rid8">8</a>]. Type 1 AIP is generally seen in males in the sixth to seventh decade of life, with elevation of serum IgG4 (&gt;2 times upper limit of normal [ULN]). In a nationwide survey of Japan that included 4297 patients, the most common clinical symptoms were painless jaundice (49 percent), abdominal pain (26 percent), extrapancreatic lesions (12 percent), weight loss (3 percent), acute pancreatitis (1 percent), or others [<a href="#rid8">8</a>]. Males were more commonly affected than females in a ratio of 3:1, and the average age of onset was 68 years. </p><p>Type 1 AIP may present as an isolated disorder or as part of an IgG4-related disease (IgG4-RD) syndrome with other organ involvement (OOI). Organs typically involved in IgG4-RD include the pancreas (type 1 AIP); bile duct (sclerosing cholangitis); submandibular, parotid, and sublingual glands (sclerosing sialadenitis); orbital area with lacrimal gland involvement (sclerosing dacryoadenitis often associated with Mikulicz disease); lung; retroperitoneum (fibrosis); and kidney (tubulo-interstitial nephritis) [<a href="#rid4">4,5,9,10</a>].</p><p class="headingAnchor" id="H3396527197"><span class="h3">Type 2 AIP</span><span class="headingEndMark"> — </span>The clinical symptoms of type 2 AIP overlap those of type 1 AIP except that the disorder is confined to the pancreas. Patients may have a cholestatic pattern of elevation in liver tests similar to type 1 AIP. Approximately 25 percent of patients with type 2 AIP have a &gt;2-fold elevation in IgG4 levels. IgG4 levels are generally normal or only mildly elevated [<a href="#rid11">11,12</a>]. Patients are typically younger than those with type 1 AIP, presenting in the third to fourth decade of life, and males and females are affected in a 1:1 ratio [<a href="#rid12">12</a>]. Type 2 AIP may present with acute pancreatitis (45 to 65 percent), jaundice (18 to 25 percent), or pain. Type 2 AIP appears to be limited to the pancreas and often co-occurs in patients with inflammatory bowel disease (IBD). In a multicenter study of 91 individuals with AIP and IBD, the majority (98 percent) had type 2 AIP [<a href="#rid13">13</a>]. Two-thirds had ulcerative colitis (UC; often with proctitis) and one-third had Crohn disease. In this series, the mean age at diagnosis of type 2 AIP was 35±12 years, younger than persons with type 1 AIP, and the sex distribution was equal. (See <a class="local">'Serum IgG4'</a> below.)</p><p class="headingAnchor" id="H2694244591"><span class="h2">Imaging findings</span><span class="headingEndMark"> — </span>AIP is usually first suggested by an imaging test such as dynamic contrast-enhanced (DCE) computed tomography (CT) or magnetic resonance imaging (MRI)  (<a class="graphic graphic_diagnosticimage graphicRef87628" href="/d/graphic/87628.html" rel="external">image 1</a>), which demonstrates a diffusely enlarged pancreas with featureless borders and delayed enhancement with or without a capsule-like rim [<a href="#rid14">14</a>]. Magnetic resonance cholangiopancreatography (MRCP) can help delineate ductal abnormalities. (See <a class="local">'Magnetic resonance cholangiopancreatography'</a> below.)</p><p class="headingAnchor" id="H2559036928"><span class="h2">Complications</span><span class="headingEndMark"> — </span>Pancreatic atrophy can develop in 25 percent of patients with AIP and may manifest as exocrine pancreatic insufficiency or pancreatogenic diabetes mellitus (type 3c). Patients with AIP do not appear to be at an increased risk for pancreatic cancer.</p><p class="headingAnchor" id="H7"><span class="h1">DIAGNOSTIC APPROACH</span></p><p class="headingAnchor" id="H2373098069"><span class="h2">When to suspect AIP</span><span class="headingEndMark"> — </span>Autoimmune pancreatitis (AIP) should be considered in patients presenting with painless jaundice and abdominal pain or a diffusely enlarged pancreas or pancreatic mass on imaging. The suspicion for AIP should be further increased in those with other autoimmune conditions.  </p><p class="headingAnchor" id="H237600595"><span class="h2">Initial evaluation</span><span class="headingEndMark"> — </span>The evaluation of patients with suspected AIP includes selected laboratory testing, pancreatic imaging with magnetic resonance cholangiopancreatography (MRCP), and endoscopic ultrasound-guided biopsy. This evaluation serves to identify the characteristic features of AIP and to exclude other disorders, particularly pancreatobiliary cancer. Even when AIP is appropriately diagnosed, 1 to 2 percent of patients will also have pancreatic cancer [<a href="#rid1">1</a>]. Among patients with immunoglobulin G4-related sclerosing cholangitis (IgG4-SC), over 20 percent present with features resembling bile duct malignancies [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H3666187612"><span class="h3">Magnetic resonance cholangiopancreatography</span><span class="headingEndMark"> — </span>MRCP is recommended for evaluation of the pancreatic duct in patients with suspected AIP [<a href="#rid16">16</a>]. As compared with abdominal CT, MRI has a higher sensitivity but a similar specificity in distinguishing AIP from pancreatic ductal adenocarcinoma [<a href="#rid17">17</a>]. Imaging should include the head, neck, thorax, abdomen, and pelvis to evaluate for involvement of other organs associated with IgG4-related disease (IgG4-RD) [<a href="#rid18">18</a>]. (See <a class="local">'Clinical features'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Parenchymal imaging</strong> – Diffuse enlargement of the pancreas with delayed enhancement is highly suggestive of AIP  (<a class="graphic graphic_diagnosticimage graphicRef130732" href="/d/graphic/130732.html" rel="external">image 2</a>). There may also be a rim-like hypoenhancement surrounding the gland  (<a class="graphic graphic_diagnosticimage graphicRef130732" href="/d/graphic/130732.html" rel="external">image 2</a>). Segmental or focal enlargement with delayed enhancement is considered indeterminate and requires additional evidence. An AIP lesion is a low signal intensity area on T1-weighted MR sequences (or occasionally speckled hyperintensity), and a hyperintense area on T2- and diffusion-weighted imaging (DWI) sequences. [<a href="#rid18">18</a>]. AIP is hypovascular on the pancreatic phase of dynamic contrast-enhanced (DCE)-CT and MRI and homogeneously enhanced on the delayed phase of DCE-CT and MRI [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ductal imaging</strong> – MRCP with or without <a class="drug drug_general" data-topicid="10259" href="/d/drug information/10259.html" rel="external">secretin</a> may reveal a normal duct but may also demonstrate a narrowed main and dorsal pancreatic duct; diffuse, irregular narrowing of the pancreatic duct (beaded appearance) or a focal stricture of the pancreatic duct or of the proximal or distal common bile duct; or irregular narrowing of the intrahepatic ducts  (<a class="graphic graphic_figure graphicRef53448" href="/d/graphic/53448.html" rel="external">figure 1</a> and <a class="graphic graphic_diagnosticimage graphicRef130732" href="/d/graphic/130732.html" rel="external">image 2</a> and <a class="graphic graphic_diagnosticimage graphicRef130734" href="/d/graphic/130734.html" rel="external">image 3</a>) [<a href="#rid19">19,20</a>]. </p><p></p><p class="bulletIndent1">Narrowing or strictures of the main pancreatic duct seen on MRCP can be long (eg, greater than one-third of the pancreatic duct length) or multiple but without significant dilatation above the narrowed area upstream of the main duct. Segmental or focal narrowing without extended areas of involvement is considered indeterminate and requires additional evidence  (<a class="graphic graphic_diagnosticimage graphicRef130734" href="/d/graphic/130734.html" rel="external">image 3</a>).   </p><p></p><p class="bulletIndent1">Cholangiographic findings of IgG4-SC can involve the hilar and/or intrahepatic bile ducts and can be similar to those of hilar cholangiocarcinoma or primary sclerosing cholangitis (PSC). Cholangiograms from patients with PSC are more likely to show band-like strictures, a beaded or pruned-tree appearance, or diverticulum-like formation [<a href="#rid21">21</a>]. By contrast, IgG4-SC strictures are more often segmental strictures, long strictures with prestenotic dilatation, and strictures of the distal common bile duct [<a href="#rid21">21-23</a>]. Ductal wall thickening and enhancement may also be seen and suggests IgG4-SC. </p><p></p><p class="headingAnchor" id="H375125162"><span class="h3">Endoscopic ultrasonography guided biopsy</span><span class="headingEndMark"> — </span>We perform endoscopic ultrasonography (EUS)-guided biopsy to rule out pancreatic cancer and obtain tissue to diagnose AIP [<a href="#rid8">8,16,24,25</a>]. In cases where imaging identifies a mass in the head of the pancreas consistent with AIP, the International Consensus Diagnostic Criteria (ICDC) guidelines recommend EUS-guided core biopsy or resection. Endoscopic biopsy of the duodenal papilla may be a useful adjunctive method because ampulla often is involved pathologically in AIP [<a href="#rid1">1</a>]. </p><p>Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) of the pancreas can provide diagnostic histology in a significant fraction of patients with type 1 AIP. Diagnosis of type 2 AIP may also be possible, but additional studies are needed [<a href="#rid26">26,27</a>]. This was illustrated in a prospective study that included 56 patients, of which 55 were suspected to have type 1 AIP and one to have type 2 AIP. Lymphoplasmacytic infiltration, obliterative phlebitis, storiform fibrosis, and &gt;10 IgG4-positive cells per high-power field (HPF) were detected in 100, 44, 73, and 66 percent, respectively. The detection rates of level 1 and level 1 or 2 histology for AIP were 58 and 93 percent, respectively  (<a class="graphic graphic_table graphicRef130443" href="/d/graphic/130443.html" rel="external">table 1</a>).</p><p>Although fine-needle aspiration (FNA) may be useful for evaluating suspicious lesions for malignancy, it may be inadequate for diagnosing AIP, especially type 2 AIP [<a href="#rid25">25,28,29</a>]. A prospective multicenter feasibility study in Japan of the use of a 22-gauge needle for the diagnosis of (type 1) AIP demonstrated the utility of this approach [<a href="#rid28">28</a>]. IgG4-positive plasma cell counts of &gt;10, 5 to 10, and 1 to 4 per HPF were obtained from 29 (37 percent), 18 (23 percent), and 15 (19 percent) of 78 patients, respectively. Storiform fibrosis was detected in 49 of 78 patients (63 percent). Obliterative phlebitis was observed in 38 of 78 patients (49 percent). Based on ICDC criteria, histopathologic levels corresponded to level 1 and 2 in 32 (41 percent) and 13 (27 percent), respectively, allowing for a histopathologic diagnosis of AIP in 58 percent of individuals  (<a class="graphic graphic_table graphicRef130440" href="/d/graphic/130440.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H3418503331"><span class="h3">Histology</span><span class="headingEndMark"> — </span>Characteristic histologic findings of AIP include the following  (<a class="graphic graphic_table graphicRef130443" href="/d/graphic/130443.html" rel="external">table 1</a>) [<a href="#rid14">14,24,30</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type 1 AIP</strong> – A lymphoplasmacytic sclerosing pancreatitis <strong>or</strong> &gt;10 IgG4-positive cells with at least two of the following: periductal lymphoplasmacytic infiltrate, obliterative phlebitis, and/or swirling collagen fibers (storiform fibrosis)  (<a class="graphic graphic_figure graphicRef130690" href="/d/graphic/130690.html" rel="external">figure 2</a> and <a class="graphic graphic_diagnosticimage graphicRef130688" href="/d/graphic/130688.html" rel="external">image 4</a>) [<a href="#rid24">24</a>]. Similar histologic findings can be found in biopsy specimens of extrapancreatic organs involved in patients with IgG4-RD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type 2 AIP </strong>– Idiopathic duct-centric pancreatitis (IDCP) is characterized by a granulocytic epithelial lesion in the pancreatic duct with minimal IgG4-positive cells in the pancreatic parenchyma  (<a class="graphic graphic_figure graphicRef130691" href="/d/graphic/130691.html" rel="external">figure 3</a>) [<a href="#rid5">5,24</a>].</p><p></p><p class="headingAnchor" id="H2158943475"><span class="h3">Laboratory testing</span></p><p class="headingAnchor" id="H2778196628"><span class="h4">Serum IgG4</span><span class="headingEndMark"> — </span>Serum IgG4 &gt;2 times the upper limit of normal (ULN; &gt;280 mg/dL) is highly suggestive of AIP [<a href="#rid14">14,31</a>]. Elevations in IgG4 &gt;2 times ULN are seen in approximately two-thirds of patients with type 1 AIP and one-fourth of patients with type 2 AIP. (See <a class="local">'Clinical features'</a> above and <a class="local">'Subtypes'</a> above.)</p><p>Elevations in serum IgG4 are not specific for AIP, and up to 10 percent of individuals with pancreatic cancer also have elevated IgG4 levels. However, only 1 percent of patients with pancreatic cancer have serum IgG4 levels above 280 mg/dL [<a href="#rid31">31-33</a>]. Patients with PSC may also have elevations in IgG4. In one series of 127 patients with PSC, 9 percent of patients had elevated serum IgG4 levels [<a href="#rid23">23</a>]. Serum IgG4 values above normal but ≤280 mg/dL have been described in a number of disorders that do not involve the pancreas, including atopic dermatitis, asthma, some parasitic diseases, pemphigus vulgaris, and pemphigus foliaceus [<a href="#rid34">34-36</a>]. The elevation in serum IgG4 levels in these patients is usually accompanied by an elevation in serum immunoglobulin E (IgE). Among patients with AIP, serum IgG4 declines during treatment with glucocorticoids [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/130656.html" rel="external">"Autoimmune pancreatitis: Management"</a>.)</p><p class="headingAnchor" id="H2620245434"><span class="h4">Other</span><span class="headingEndMark"> — </span>We do not routinely perform additional serologic tests to diagnose AIP or to exclude a pancreatic malignancy. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cancer-associated antigen 19-9 (CA19-9)</strong> – CA19-9 is a tumor marker commonly associated with pancreatic cancer. However, patients with specific inactivating genetic variants in fucosyltransferase 3 (<em>FUT3)</em> may have minimal or absent CA19-9 levels, while inactivating mutations in <em>FUT2</em> have higher than normal CA19-9 levels [<a href="#rid37">37-39</a>]. Thus, CA19-9 is not always elevated in pancreatic cancer or other conditions. (See  <a class="medical medical_review" href="/d/html/2501.html" rel="external">"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer", section on 'Carbohydrate antigen 19-9'</a>.)</p><p></p><p class="bulletIndent1">In a study of 123 type 1 AIP patients followed for a median of 55 months, two developed pancreatic cancer a year or more after AIP diagnosis and treatment. CA19-9 at initial diagnosis of AIP was normal in patients not progressing to pancreatic cancer (median, 21 U/mL [interquartile range, 8.25 to 36.25]). Levels were elevated in the two patients with pancreatic cancer (median 220.5 U/mL, [range 117 to 324]) [<a href="#rid40">40</a>]. The CA19-9 was the only feature that distinguished these patients. Of note, the two patients in whom cancer developed had IgG4 levels at initial diagnosis of AIP that were at the higher range of IgG4 levels in the cohort. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-IgG4 antibodies</strong> – Antibodies that are variably elevated in patients with AIP include anti-plasminogen-binding protein (PBP) peptide antibodies (94 percent) [<a href="#rid41">41</a>], antibodies to carbonic anhydrase II antigens (30 to 59 percent) [<a href="#rid42">42</a>], and lactoferrin (50 to 76 percent) [<a href="#rid43">43</a>]. Other antibodies that have been associated with AIP, but that have not been consistently positive, include rheumatoid factor, perinuclear antineutrophil cytoplasmic antibodies, antinuclear antibodies, antimitochondrial antibodies, anti-smooth muscle antibodies, and antithyroglobulin [<a href="#rid44">44-46</a>]. IgG4/IgG RNA ratio does not accurately discriminate IgG4-RD from pancreatobiliary cancer [<a href="#rid47">47</a>]. </p><p></p><p class="headingAnchor" id="H11353565"><span class="h3">Glucocorticoid trial</span><span class="headingEndMark"> — </span>A glucocorticoid trial should be conducted only in patients with a negative work-up for pancreatic cancer. Cancer can mask as AIP and patients with AIP can have cancer concurrently. In patients with equivocal evidence of AIP and features concerning for pancreatic cancer (eg, age over 60 years, focal pancreatic involvement, moderately elevated IgG4, and no evidence of other organ involvement [OOI]), the probability of pancreatic cancer approaches 95 percent. In our practice, we use EUS-FNB in an attempt to make a diagnosis of pancreatic adenocarcinoma, since elevated serum and IgG4-postive cells on cytology can often be seen in patients with pancreatic cancer. In individuals with suspected AIP, we do not initiate a diagnostic trial of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> until there are <strong>two</strong> negative EUS-FNBs with adequate cytologic/pathologic specimens. (See <a class="local">'Endoscopic ultrasonography guided biopsy'</a> above.)</p><p>A response to a course of glucocorticoids (<a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 40 mg daily), characterized by radiologic resolution or marked improvement in pancreatic/extrapancreatic manifestations, strongly supports the diagnosis of AIP. The lack of response to a glucocorticoid trial within two to three weeks warrants referral for surgical exploration for pancreatic cancer [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/d/html/130656.html" rel="external">"Autoimmune pancreatitis: Management", section on 'Assessment of response to therapy'</a>.)</p><p class="headingAnchor" id="H2427605260"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of AIP is based on histology in the setting of supportive serologic studies (elevated IgG4) and imaging after the exclusion of alternative diagnoses. Diagnostic criteria for AIP, proposed by the International Association of Pancreatology in 2011 with subsequent modifications recommended by Japanese experts for simplicity, use findings on imaging of pancreatic parenchyma and the pancreatic duct, serology, OOI associated with IgG4-RD, pancreatic histology, and an optional criterion of response to glucocorticoid therapy to diagnose and classify AIP  (<a class="graphic graphic_table graphicRef130443" href="/d/graphic/130443.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef130440" href="/d/graphic/130440.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef130444" href="/d/graphic/130444.html" rel="external">table 3</a>) [<a href="#rid1">1,16</a>]. The criteria are traditionally referred to as the HISORt (histology, imaging, serology, other organ involvement, and response to steroid therapy) criteria. The diagnosis of AIP and its subtypes are considered definitive or probable based on the specific findings. (See <a class="local">'Subtypes'</a> above and <a class="local">'Clinical features'</a> above.)</p><p>Diagnostic criteria for AIP have limitations in sensitivity (85 percent in one series) [<a href="#rid49">49</a>]. Clinicians should also consider the possibility of multiple conditions occurring in the same person (eg, AIP and cancer). The diagnosis, therefore, requires careful reassessment in the absence of response to treatment. (See <a class="local">'Glucocorticoid trial'</a> above.)</p><p class="headingAnchor" id="H279922129"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The main differential diagnosis of concern for both AIP and IgG4-SC are pancreatobiliary cancers. Clinical and imaging features can often differentiate AIP from pancreatic cancer and chronic pancreatitis  (<a class="graphic graphic_table graphicRef130447" href="/d/graphic/130447.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef130453" href="/d/graphic/130453.html" rel="external">table 5</a>). The differential diagnosis of IgG4-RD is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/121220.html" rel="external">"Clinical manifestations and diagnosis of IgG4-related disease", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H924301647"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112065.html" rel="external">"Society guideline links: Chronic pancreatitis and pancreatic exocrine insufficiency"</a> and  <a class="medical medical_society_guidelines" href="/d/html/117964.html" rel="external">"Society guideline links: IgG4-related disease"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune pancreatitis (AIP) is an uncommon but well-established form of pancreatic inflammation. Unlike other pancreatic diseases, it typically has a dramatic response to glucocorticoid therapy. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with AIP most commonly present with painless obstructive jaundice. More than one-third of cases are discovered in asymptomatic patients undergoing evaluation for a pancreatic mass, pancreatic enlargement, or pancreatic duct strictures on abdominal imaging; a cholestatic pattern of liver test elevation; or diabetes mellitus. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type 1 AIP is defined histologically as lymphoplasmacytic sclerosing pancreatitis (LPSP). Type 1 AIP may present as an isolated disorder or as part of an immunoglobulin G4-related disease (IgG4-RD) syndrome with other organ involvement (OOI). Organs typically involved in IgG4-RD include the pancreas (type 1 AIP); bile duct (sclerosing cholangitis); submandibular, parotid, and sublingual glands (sclerosing sialadenitis); orbital area with lacrimal gland involvement (sclerosing dacryoadenitis often associated with Mikulicz disease); lung; retroperitoneum (fibrosis); and kidney (tubulo-interstitial nephritis). Type 2 AIP is defined histologically as idiopathic duct-centric pancreatitis (IDCP) or AIP with granulocyte epithelial lesions (GELs). Type 2 AIP appears to be limited to the pancreas and often co-occurs in patients with inflammatory bowel disease (IBD). (See <a class="local">'Histology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of AIP should be considered in patients presenting with painless jaundice, abdominal pain, and in patients with a diffusely enlarged pancreas or pancreatic mass on imaging. The suspicion for AIP should be further increased in those with IBD. (See <a class="local">'When to suspect AIP'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The evaluation of patients with suspected AIP includes selected laboratory testing, pancreatic imaging with multiphase CT or magnetic resonance imaging with cholangiopancreatography (MRCP), and endoscopic ultrasound-guided biopsy. This evaluation serves to identify the characteristic features of AIP and to exclude other disorders, particularly pancreatobiliary cancer. (See <a class="local">'Diagnostic approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of AIP is based on histology in the setting of supportive serologic studies (elevated IgG4) and imaging after the exclusion of alternative diagnoses. Diagnostic criteria for AIP use findings on imaging of pancreatic parenchyma and duct, serology, OOI, pancreatic histology, and an optional criterion of response to glucocorticoid therapy to diagnose and classify AIP  (<a class="graphic graphic_table graphicRef130443" href="/d/graphic/130443.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef130440" href="/d/graphic/130440.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef130444" href="/d/graphic/130444.html" rel="external">table 3</a>). The lack of response to a glucocorticoid trial warrants referral for surgical exploration for pancreatic cancer. (See <a class="local">'Diagnostic approach'</a> above and  <a class="medical medical_review" href="/d/html/130656.html" rel="external">"Autoimmune pancreatitis: Management", section on 'Assessment of response to therapy'</a>.)</p><p></p><p class="headingAnchor" id="H3930442590"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Norton Greenberger, MD, and David C Whitcomb, MD, PhD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas 2011; 40:352.</a></li><li><a class="nounderline abstract_t">de Pretis N, Vieceli F, Brandolese A, et al. Autoimmune pancreatitis not otherwise specified (NOS): clinical features and outcomes of the forgotten type. Hepatobiliary Pancreat Dis Int 2019; 18:576.</a></li><li><a class="nounderline abstract_t">Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 2012; 22:21.</a></li><li><a class="nounderline abstract_t">Miyabe K, Zen Y, Cornell LD, et al. Gastrointestinal and extra-intestinal manifestations of IgG4-related disease. Gastroenterology 2018; 155:990.</a></li><li><a class="nounderline abstract_t">Maritati F, Peyronel F, Vaglio A. IgG4-related disease: a clinical perspective. Rheumatology (Oxford) 2020; 59:iii123.</a></li><li><a class="nounderline abstract_t">Nakazawa T, Naitoh I, Hayashi K, et al. Diagnostic criteria for IgG4-related sclerosing cholangitis based on cholangiographic classification. J Gastroenterol 2012; 47:79.</a></li><li><a class="nounderline abstract_t">Kamisawa T, Nakazawa T, Tazuma S, et al. Clinical practice guidelines for IgG4-related sclerosing cholangitis. J Hepatobiliary Pancreat Sci 2019; 26:9.</a></li><li><a class="nounderline abstract_t">Masamune A, Kikuta K, Hamada S, et al. Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2016. J Gastroenterol 2020; 55:462.</a></li><li><a class="nounderline abstract_t">Phaopraphat K, Ngamjanyaporn P, Narongroeknawin P, et al. Clinical manifestations, clinical course, and outcomes of immunoglobulin G4-related disease. Int J Rheum Dis 2020; 23:1468.</a></li><li><a class="nounderline abstract_t">Chen LYC, Mattman A, Seidman MA, Carruthers MN. IgG4-related disease: what a hematologist needs to know. Haematologica 2019; 104:444.</a></li><li><a class="nounderline abstract_t">Umachandran V, Ranjadayalan K, Ambepityia G, et al. The perception of angina in diabetes: relation to somatic pain threshold and autonomic function. Am Heart J 1991; 121:1649.</a></li><li><a class="nounderline abstract_t">de Pretis N, Frulloni L. Autoimmune pancreatitis type 2. Curr Opin Gastroenterol 2020; 36:417.</a></li><li><a class="nounderline abstract_t">Lorenzo D, Maire F, Stefanescu C, et al. Features of Autoimmune Pancreatitis Associated With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2018; 16:59.</a></li><li><a class="nounderline abstract_t">Chari ST, Takahashi N, Levy MJ, et al. A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. Clin Gastroenterol Hepatol 2009; 7:1097.</a></li><li><a class="nounderline abstract_t">Ali AH, Bi Y, Machicado JD, et al. The long-term outcomes of patients with immunoglobulin G4-related sclerosing cholangitis: the Mayo Clinic experience. J Gastroenterol 2020; 55:1087.</a></li><li><a class="nounderline abstract_t">Kawa S, Kamisawa T, Notohara K, et al. Japanese Clinical Diagnostic Criteria for Autoimmune Pancreatitis, 2018: Revision of Japanese Clinical Diagnostic Criteria for Autoimmune Pancreatitis, 2011. Pancreas 2020; 49:e13.</a></li><li><a class="nounderline abstract_t">Ha J, Choi SH, Byun JH, et al. Meta-analysis of CT and MRI for differentiation of autoimmune pancreatitis from pancreatic adenocarcinoma. Eur Radiol 2021; 31:3427.</a></li><li><a class="nounderline abstract_t">Takahashi M, Fujinaga Y, Notohara K, et al. Diagnostic imaging guide for autoimmune pancreatitis. Jpn J Radiol 2020; 38:591.</a></li><li><a class="nounderline abstract_t">Horiuchi A, Kawa S, Hamano H, et al. ERCP features in 27 patients with autoimmune pancreatitis. Gastrointest Endosc 2002; 55:494.</a></li><li><a class="nounderline abstract_t">Kamisawa T, Tu Y, Egawa N, et al. Involvement of pancreatic and bile ducts in autoimmune pancreatitis. World J Gastroenterol 2006; 12:612.</a></li><li><a class="nounderline abstract_t">Nakazawa T, Ohara H, Sano H, et al. Cholangiography can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis. Gastrointest Endosc 2004; 60:937.</a></li><li><a class="nounderline abstract_t">Nakazawa T, Ohara H, Sano H, et al. Clinical differences between primary sclerosing cholangitis and sclerosing cholangitis with autoimmune pancreatitis. Pancreas 2005; 30:20.</a></li><li><a class="nounderline abstract_t">Mendes FD, Jorgensen R, Keach J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006; 101:2070.</a></li><li><a class="nounderline abstract_t">Notohara K, Kamisawa T, Fukushima N, et al. Guidance for diagnosing autoimmune pancreatitis with biopsy tissues. Pathol Int 2020; 70:699.</a></li><li><a class="nounderline abstract_t">Cao L, Wang Y, Wang J, et al. The role of EUS-guided fine needle aspiration in autoimmune pancreatitis: a single center prospective study. Scand J Gastroenterol 2018; 53:1604.</a></li><li><a class="nounderline abstract_t">Kurita A, Yasukawa S, Zen Y, et al. Comparison of a 22-gauge franseen-tip needle with a 20-gauge forward-bevel needle for the diagnosis of type 1 autoimmune pancreatitis: a prospective, randomized, controlled, multicenter study (COMPAS study). Gastrointest Endosc 2020; 91:373.</a></li><li><a class="nounderline abstract_t">Ishikawa T, Kawashima H, Ohno E, et al. Usefulness of endoscopic ultrasound-guided fine-needle biopsy for the diagnosis of autoimmune pancreatitis using a 22-gauge franseen needle: a prospective multicenter study. Endoscopy 2020; 52:978.</a></li><li><a class="nounderline abstract_t">Kanno A, Masamune A, Fujishima F, et al. Diagnosis of autoimmune pancreatitis by EUS-guided FNA using a 22-gauge needle: a prospective multicenter study. Gastrointest Endosc 2016; 84:797.</a></li><li><a class="nounderline abstract_t">Suk Lee Y, Kim NH, Hyuk Son J, et al. Type 2 autoimmune pancreatitis with crohn's disease. Intern Med 2018; 57:2957.</a></li><li><a class="nounderline abstract_t">Esposito I, Hruban RH, Verbeke C, et al. Guidelines on the histopathology of chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and the European Pancreatic Club. Pancreatology 2020; 20:586.</a></li><li><a class="nounderline abstract_t">Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001; 344:732.</a></li><li><a class="nounderline abstract_t">Ghazale A, Chari ST, Smyrk TC, et al. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am J Gastroenterol 2007; 102:1646.</a></li><li><a class="nounderline abstract_t">Raina A, Krasinskas AM, Greer JB, et al. Serum immunoglobulin G fraction 4 levels in pancreatic cancer: elevations not associated with autoimmune pancreatitis. Arch Pathol Lab Med 2008; 132:48.</a></li><li><a class="nounderline abstract_t">Aalberse RC, Van Milligen F, Tan KY, Stapel SO. Allergen-specific IgG4 in atopic disease. Allergy 1993; 48:559.</a></li><li><a class="nounderline abstract_t">Rock B, Martins CR, Theofilopoulos AN, et al. The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus (fogo selvagem). N Engl J Med 1989; 320:1463.</a></li><li><a class="nounderline abstract_t">Bhol K, Mohimen A, Ahmed AR. Correlation of subclasses of IgG with disease activity in pemphigus vulgaris. Dermatology 1994; 189 Suppl 1:85.</a></li><li><a class="nounderline abstract_t">Narimatsu H, Iwasaki H, Nakayama F, et al. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res 1998; 58:512.</a></li><li><a class="nounderline abstract_t">Indellicato R, Zulueta A, Caretti A, Trinchera M. Complementary use of carbohydrate antigens Lewis a, Lewis b, and Sialyl-Lewis a (CA19.9 Epitope) in gastrointestinal cancers: biological rationale towards a personalized clinical application. Cancers (Basel) 2020; 12.</a></li><li><a class="nounderline abstract_t">Abe T, Koi C, Kohi S, et al. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol 2020; 18:1161.</a></li><li><a class="nounderline abstract_t">Ishikawa T, Kawashima H, Ohno E, et al. Risks and characteristics of pancreatic cancer and pancreatic relapse in autoimmune pancreatitis patients. J Gastroenterol Hepatol 2020; 35:2281.</a></li><li><a class="nounderline abstract_t">Frulloni L, Lunardi C, Simone R, et al. Identification of a novel antibody associated with autoimmune pancreatitis. N Engl J Med 2009; 361:2135.</a></li><li><a class="nounderline abstract_t">Kino-Ohsaki J, Nishimori I, Morita M, et al. Serum antibodies to carbonic anhydrase I and II in patients with idiopathic chronic pancreatitis and Sjögren's syndrome. Gastroenterology 1996; 110:1579.</a></li><li><a class="nounderline abstract_t">Kim KP, Kim MH, Song MH, et al. Autoimmune chronic pancreatitis. Am J Gastroenterol 2004; 99:1605.</a></li><li><a class="nounderline abstract_t">Uchida K, Okazaki K, Konishi Y, et al. Clinical analysis of autoimmune-related pancreatitis. Am J Gastroenterol 2000; 95:2788.</a></li><li><a class="nounderline abstract_t">Deshpande V, Mino-Kenudson M, Brugge W, Lauwers GY. Autoimmune pancreatitis: more than just a pancreatic disease? A contemporary review of its pathology. Arch Pathol Lab Med 2005; 129:1148.</a></li><li><a class="nounderline abstract_t">Yoshida K, Toki F, Takeuchi T, et al. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci 1995; 40:1561.</a></li><li><a class="nounderline abstract_t">de Vries E, Tielbeke F, Hubers L, et al. IgG4/IgG RNA ratio does not accurately discriminate IgG4-related disease from pancreatobiliary cancer. JHEP Rep 2020; 2:100116.</a></li><li><a class="nounderline abstract_t">Moon SH, Kim MH, Park DH, et al. Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective outcome study. Gut 2008; 57:1704.</a></li><li><a class="nounderline abstract_t">Raina A, Yadav D, Krasinskas AM, et al. Evaluation and management of autoimmune pancreatitis: experience at a large US center. Am J Gastroenterol 2009; 104:2295.</a></li></ol></div><div id="topicVersionRevision">Topic 5657 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21412117" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31248720" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Autoimmune pancreatitis not otherwise specified (NOS): Clinical features and outcomes of the forgotten type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22218969" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30012334" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Gastrointestinal and Extra-Intestinal Manifestations of IgG4-Related Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32348524" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : IgG4-related disease: a clinical perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21947649" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Diagnostic criteria for IgG4-related sclerosing cholangitis based on cholangiographic classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30575336" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical practice guidelines for IgG4-related sclerosing cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31872350" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32808722" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical manifestations, clinical course, and outcomes of immunoglobulin G4-related disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30705099" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : IgG4-related disease: what a hematologist needs to know.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2035379" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The perception of angina in diabetes: relation to somatic pain threshold and autonomic function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32618613" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Autoimmune pancreatitis type 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28782667" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Features of Autoimmune Pancreatitis Associated With Inflammatory Bowel Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19410017" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32770464" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The long-term outcomes of patients with immunoglobulin G4-related sclerosing cholangitis: the Mayo Clinic experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31856100" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Japanese Clinical Diagnostic Criteria for Autoimmune Pancreatitis, 2018: Revision of Japanese Clinical Diagnostic Criteria for Autoimmune Pancreatitis, 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33146798" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Meta-analysis of CT and MRI for differentiation of autoimmune pancreatitis from pancreatic adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32297064" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Diagnostic imaging guide for autoimmune pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11923760" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : ERCP features in 27 patients with autoimmune pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16489677" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Involvement of pancreatic and bile ducts in autoimmune pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15605009" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cholangiography can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15632695" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical differences between primary sclerosing cholangitis and sclerosing cholangitis with autoimmune pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16879434" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32767550" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Guidance for diagnosing autoimmune pancreatitis with biopsy tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30422724" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The role of EUS-guided fine needle aspiration in autoimmune pancreatitis: a single center prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31654634" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Comparison of a 22-gauge Franseen-tip needle with a 20-gauge forward-bevel needle for the diagnosis of type 1 autoimmune pancreatitis: a prospective, randomized, controlled, multicenter study (COMPAS study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32583394" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Usefulness of endoscopic ultrasound-guided fine-needle biopsy for the diagnosis of autoimmune pancreatitis using a 22-gauge Franseen needle: a prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27068878" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Diagnosis of autoimmune pancreatitis by EUS-guided FNA using a 22-gauge needle: a prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29526939" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Type 2 Autoimmune Pancreatitis with Crohn's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32414657" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Guidelines on the histopathology of chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and the European Pancreatic Club.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11236777" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : High serum IgG4 concentrations in patients with sclerosing pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17555461" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18181673" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Serum immunoglobulin G fraction 4 levels in pancreatic cancer: elevations not associated with autoimmune pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8116855" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Allergen-specific IgG4 in atopic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2654636" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus (fogo selvagem).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8049571" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Correlation of subclasses of IgG with disease activity in pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9458099" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32527016" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Complementary Use of Carbohydrate Antigens Lewis a, Lewis b, and Sialyl-Lewis a (CA19.9 Epitope) in Gastrointestinal Cancers: Biological Rationale Towards A Personalized Clinical Application.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31676359" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32583452" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Risks and characteristics of pancreatic cancer and pancreatic relapse in autoimmune pancreatitis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19940298" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Identification of a novel antibody associated with autoimmune pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8613065" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Serum antibodies to carbonic anhydrase I and II in patients with idiopathic chronic pancreatitis and Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15307882" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Autoimmune chronic pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11051349" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Clinical analysis of autoimmune-related pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16119989" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Autoimmune pancreatitis: more than just a pancreatic disease? A contemporary review of its pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7628283" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32642635" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : IgG4/IgG RNA ratio does not accurately discriminate IgG4-related disease from pancreatobiliary cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18583399" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective outcome study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19532132" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Evaluation and management of autoimmune pancreatitis: experience at a large US center.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
